<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088307</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIOLIFE--001</org_study_id>
    <nct_id>NCT02088307</nct_id>
  </id_info>
  <brief_title>Study of the Cardiovascular Vitamin, CardioLife</brief_title>
  <official_title>Evaluation of the Metabolic and Physiological Profiles of Patients Diagnosed With Cardiovascular Disease (CVD) Following Administration of the Novel Cardiovascular Vitamin, CardioLife</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the metabolic and physiological characteristics of patients with diagnosed&#xD;
      Cardiovascular Disease following administration of the Cardiovascular vitamin, CardioLife.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to evaluate the safety and efficacy of cardiovascular nutraceutical&#xD;
      supplement, CardioLife™ in patients with diagnosed Cardiovascular Disease (CVD). CardioLife&#xD;
      is a novel nutraceutical intended for the prevention and management of cardiovascular risk&#xD;
      factors, enhancement of cardiac performance and the treatment of cardiac dysfunction. This is&#xD;
      an oral vitamin supplement comprising of the following main ingredients: garlic co-enzyme&#xD;
      Q10, Arjuna, Hawthorn, Guggul, Red Yeast Rice, Policosanol, Nattokinase, Tumeric/curcumin,&#xD;
      ashangandha, L-carnitine, grape seed extract, and vitamin B12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipid levels</measure>
    <time_frame>Baseline to 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change plasma levels of endothelial progenitor cells (EPC)</measure>
    <time_frame>Baseline to 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cholesterol levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homocysteine levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erythrocyte sedimentation rate (ESR) levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hs-C-reactive protein (CRP) levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the control arm will not receive an intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CardioLife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CardioLife</intervention_name>
    <description>Participants randomized to treatment arm will take dietary supplement as instructed.</description>
    <arm_group_label>CardioLife</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 90 years old and ability to understand the planned study.&#xD;
&#xD;
          -  Patients with Cardiovascular Disease&#xD;
&#xD;
          -  Able to comply with all study-related visits&#xD;
&#xD;
          -  Able to give Informed Consent&#xD;
&#xD;
          -  Negative for HcG with a serum pregnancy test&#xD;
&#xD;
          -  If the patient has diabetes mellitus it must be controlled (HbA1c &lt; 9.0%)&#xD;
&#xD;
          -  Life expectancy of 1 year or more in the opinion of the investigator.&#xD;
&#xD;
          -  Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Serum&#xD;
             bilirubin, ALT, AST x 2.5 time the upper level of normal.&#xD;
&#xD;
          -  Controlled blood pressure (systolic blood pressure ≤160 and a diastolic blood pressure&#xD;
             of ≤100 mmHG) and established anti-hypertensive therapy as necessary prior to entry&#xD;
             into the study&#xD;
&#xD;
          -  Patient must be on at least three of the listed medications for at least 30 days with&#xD;
             no new medications to treat the disease introduced in the last month. Medications are:&#xD;
             Anti-Platelet Therapy, Beta-Blockers, ACE/ARB, Calcium Blocker, Nitrates, After Load&#xD;
             Reducing Agents, Lipid Lowering Agents, and/or Diuretics. Cardiac medications must be&#xD;
             at stable doses with no dose change within the last 30 days.&#xD;
&#xD;
        Pre-existing condition (e.g. thromboembolic risk, diabetes, hypercholesterolemia are&#xD;
        adequately controlled in the opinion of the investigator)&#xD;
&#xD;
          -  Fertile patients (male and female) must agree to use an appropriate form of&#xD;
             contraception while participating in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female who is pregnant or nursing, or of child bearing potential and is not using a&#xD;
             reliable birth control method, or who intend to become pregnant during the tenure of&#xD;
             this study.&#xD;
&#xD;
          -  End stage renal disease (Creatinine ≤ 3.0 mg / dl) and/or dialysis&#xD;
&#xD;
          -  Acute Myocardial Infarction 90 days prior to randomization.&#xD;
&#xD;
          -  Inability or unwillingness to comply with the treatment protocol, follow-up, research&#xD;
             tests, or give consent.&#xD;
&#xD;
          -  Life expectancy &lt;1 year due to concomitant illnesses&#xD;
&#xD;
          -  Known cancer or malignancy within the last 5 years&#xD;
&#xD;
          -  Prior admission for substance abuse&#xD;
&#xD;
          -  Uncontrolled lipid levels as determined by the Investigator&#xD;
&#xD;
          -  Untreated Hypothyroidism&#xD;
&#xD;
          -  Known Congenital Heart Defects&#xD;
&#xD;
          -  History of Ischemic and Non-Ischemic Cardiomyopathy or Heart Failure&#xD;
&#xD;
          -  Body Mass Index (BMI) of 45 kg/m2 or greater&#xD;
&#xD;
          -  Medication use of steroids 30 days prior to enrollment&#xD;
&#xD;
          -  Current use of any Nutraceutical that contains ingredients known to affect blood&#xD;
             pressure, or any active ingredients that are found in CardioLifeTM&#xD;
&#xD;
          -  Patient receiving experimental medication or participating in another clinical study&#xD;
             within 30 days of signing the informed consent&#xD;
&#xD;
          -  In the opinion of the investigator or the sponsor, the patient is unsuitable for&#xD;
             cellular therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anwar Tandar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Hospitals and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Anwar Tandar</investigator_full_name>
    <investigator_title>Assistant Professor (Clinical), Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>cardiovascular supplement</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

